FDA cardiovascular indication for semaglutide led to short-term uptake but persistent treatment gaps among high-risk patients, new Truveta study finds
BELLEVUE, Wash.—February 10, 2026—A new peer-reviewed study led by Truveta Research and collaborators finds that the US Food and Drug Administration’s (FDA) March 2024 expansion of…
Truveta deepens regulatory science leadership with appointment of John D. Seeger, PharmD, DrPH, FISPE as Senior Vice President of Evidence Services
Globally recognized pharmacoepidemiologist brings decades of experience advancing real-world evidence for regulatory decision-making. BELLEVUE, Wash.—February 9, 2026—Truveta today announced the appointment of John D. Seeger, PharmD,…
Truveta Research study published in Contraception advances understanding of women’s health and clinical guideline adoption
BELLEVUE, Wash.—February 2, 2026—Truveta today announced the publication of a new Truveta Research study in Contraception, a leading peer-reviewed journal in reproductive health. The study leverages…
Truveta launches real-time clinical trials solution to accelerate study design, enrollment, and evidence generation
Bellevue, WA — January 27, 2026 — Truveta today announced the launch of its new clinical trials solution that enables trial sponsors to design, optimize, and…
Truveta deepens oncology and scientific leadership with appointment of Johnathan Lancaster, MD, PhD as President and Chief Scientific Officer
Veteran physician–scientist brings decades of experience advancing oncology and genomics research across industry and academia. BELLEVUE, Wash. — January 26, 2026 — Truveta today announced the…
Truveta launches Truveta Live Link
A breakthrough prospective research model that unites proprietary data, real-world clinical evidence, expert determination, and integrated storage in one solution BELLEVUE, Wash.—January 13, 2026—Truveta, the health…
New Truveta research published in JAMA Network Open reveals declining timeliness in childhood MMR vaccination and identifies early predictors of missed immunizations
BELLEVUE, Wash.—January 2, 2026—Truveta today announced the publication of new peer-reviewed research in JAMA Network Open that provides one of the most comprehensive and timely analyses…
Truveta research published in JAMA Network Open shows rapid uptake of early measles vaccination during Texas outbreak
Truveta’s analysis of early measles, mumps, and rubella (MMR) vaccinations among Texas infants published today in JAMA Network Open. The study reveals a sharp increase in…
Truveta research published in Radiology Advances introduces new AI model to estimate body composition from chest radiographs
Truveta is proud to announce the publication of its latest peer-reviewed research in Radiology Advances: “XComposition: Multimodal Deep Learning Model to Measure Body Composition Using Chest…
Regulatory-grade device evidence reimagined with new precision data from Truveta
Unique device identifier data linked with ADT and chargemaster data give medical device manufacturers unmatched visibility into device use, safety, and outcomes—accelerating regulatory submissions, discovering safety…
New study reveals shift in pediatric obesity treatment following AAP guidelines
BELLEVUE, Wash.—July 14, 2025—A groundbreaking study published today in Pediatrics Open Science shows a notable increase in the use of medication to treat pediatric obesity in…
A new era in cancer research: Truveta offers the most complete, representative, and timely real-world data on all cancers
BELLEVUE, Wash. – May 8, 2025 – Today, Truveta announced a new era in cancer research with more than 7 million oncology patient journeys spanning more…
A new Truveta study offers a hopeful sign: Syphilis incidence is down for the first time in decades
Published in the American Journal of Preventative Medicine, the new study shows that for the first time since its peak in 2022, syphilis incidence has declined,…
New Truveta data and capabilities help researchers accelerate scientifically rigorous research
BELLEVUE, Wash. – March 26, 2025 – Today, Truveta announced that Truveta Data has expanded to include new administrative data to enable more comprehensive analyses of…
Truveta Data expands beyond EHR data with linked closed claims for more than 200 million patients
Closed claims complete the longitudinal patient journey in Truveta Data, enabling regulatory grade safety and effectiveness studies, replacing clinical trials and registries BELLEVUE, Wash. – February…
New Truveta study highlights patterns of discontinuation and reinitiation of GLP-1 RA medications
New research published in JAMA Network Open led by Truveta Research and Ezekiel Emanuel, MD, PhD, Perelman School of Medicine at University of Pennsylvania BELLEVUE, Wash.…
US health systems announce the Truveta Genome Project, creating the world’s largest and most diverse database to discover the science of humanity
Truveta achieves HITRUST r2 Certification, demonstrating the highest level of information protection assurance
HITRUST r2 Certification demonstrates Truveta’s relentless commitment to the highest standards of security and privacy to protect regulatory-grade data. BELLEVUE, Wash. – November 20, 2024 –…
Truveta Data, the most complete, timely, and clean electronic health record data, now includes more than 120 million de-identified patients
Researchers with more than 100 organizations use regulatory-grade Truveta Data to enable their scientifically rigorous research BELLEVUE, Wash. – November 14, 2024 –Truveta announced today that…
Truveta Studio now includes Truveta Tru, a research assistant powered by generative AI
Trained on the Truveta Language Model and Truveta Data, the most complete and representative EHR data, Tru enables researchers to accelerate their research in Truveta Studio…
The CHOICE Institute partners with Truveta to advance health economics and outcomes research
Truveta will enable The CHOICE Institute with complete, timely, and clean real-world data to improve patient care and advance medicine The Comparative Health Outcomes, Policy, and…
Truveta’s real-world data study comparing tirzepatide (Mounjaro) and semaglutide (Ozempic) for weight loss published in JAMA Internal Medicine
In the largest comparative effectiveness study of tirzepatide (Mounjaro) and semaglutide (Ozempic) for weight loss using real-world data – now published in JAMA Internal Medicine –…
Truveta announces support for regulatory submissions to the FDA and global regulatory authorities
With industry-leading certifications and rigorous third-party audits, Truveta announces new capabilities to enable successful regulatory submissions and audits. BELLEVUE, Wash. – June 18, 2024 – Today,…
Truveta welcomes Rod Hochman, MD, president and CEO of Providence, as new Truveta Board of Directors Chair
BELLEVUE, Wash. – May 13, 2024 – Today Truveta, a growing collective of more than 30 health systems with a mission of Saving Lives with Data,…